These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32557557)

  • 21. [Resolution of inflammation--pharmacological aspects].
    Leon MM; Jaba IM; Cozma CD; Albu E; Bahnea R; Mungiu OC
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):470-6. PubMed ID: 21870743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resolvins, Protectins, and Maresins: DHA-Derived Specialized Pro-Resolving Mediators, Biosynthetic Pathways, Synthetic Approaches, and Their Role in Inflammation.
    Ferreira I; Falcato F; Bandarra N; Rauter AP
    Molecules; 2022 Mar; 27(5):. PubMed ID: 35268778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis.
    Bonavita AG
    Med Hypotheses; 2020 Dec; 145():110352. PubMed ID: 33129009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.
    Serhan CN
    Annu Rev Immunol; 2007; 25():101-37. PubMed ID: 17090225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resolvins as proresolving inflammatory mediators in cardiovascular disease.
    Capó X; Martorell M; Busquets-Cortés C; Tejada S; Tur JA; Pons A; Sureda A
    Eur J Med Chem; 2018 Jun; 153():123-130. PubMed ID: 28732558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19.
    Andreakos E; Papadaki M; Serhan CN
    Allergy; 2021 Mar; 76(3):626-628. PubMed ID: 32956495
    [No Abstract]   [Full Text] [Related]  

  • 27. Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases.
    Perucci LO; Sugimoto MA; Gomes KB; Dusse LM; Teixeira MM; Sousa LP
    Expert Opin Ther Targets; 2017 Sep; 21(9):879-896. PubMed ID: 28786708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation.
    Motwani MP; Colas RA; George MJ; Flint JD; Dalli J; Richard-Loendt A; De Maeyer RP; Serhan CN; Gilroy DW
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Covid-19 management with inflammation resolving mediators? Perspectives and potential.
    Regidor PA
    Med Hypotheses; 2020 Sep; 142():109813. PubMed ID: 32416413
    [No Abstract]   [Full Text] [Related]  

  • 30. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.
    Soni S; Dyck JRB
    Can J Cardiol; 2020 Oct; 36(10):1691.e3. PubMed ID: 32717278
    [No Abstract]   [Full Text] [Related]  

  • 31. The inflammatory response triggered by Influenza virus: a two edged sword.
    Tavares LP; Teixeira MM; Garcia CC
    Inflamm Res; 2017 Apr; 66(4):283-302. PubMed ID: 27744631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.
    Almerie MQ; Kerrigan DD
    Med Hypotheses; 2020 Oct; 143():109883. PubMed ID: 32492562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protectins PCTR1 and PD1 Reduce Viral Load and Lung Inflammation During Respiratory Syncytial Virus Infection in Mice.
    Walker KH; Krishnamoorthy N; Brüggemann TR; Shay AE; Serhan CN; Levy BD
    Front Immunol; 2021; 12():704427. PubMed ID: 34489955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endogenous lipid mediators in the resolution of airway inflammation.
    Haworth O; Levy BD
    Eur Respir J; 2007 Nov; 30(5):980-92. PubMed ID: 17978156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.
    DiNicolantonio JJ; Barroso J; McCarty M
    Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterizing the anti-inflammatory and tissue protective actions of a novel Annexin A1 peptide.
    Perretti M; Di Filippo C; D'Amico M; Dalli J
    PLoS One; 2017; 12(4):e0175786. PubMed ID: 28407017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Audio Interview: Tocilizumab and Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-inflammatory effects of docosahexaenoic acid: Implications for its cancer chemopreventive potential.
    Yum HW; Na HK; Surh YJ
    Semin Cancer Biol; 2016 Oct; 40-41():141-159. PubMed ID: 27546289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathways involved in the resolution of inflammatory joint disease.
    Haworth O; Buckley CD
    Semin Immunol; 2015 May; 27(3):194-9. PubMed ID: 25944272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.